LLY
Eli Lilly and Company
LLY has the edge over PAHC overall, supported by stronger fundamentals and lower modeled downside.
PAHC
Phibro Animal Health Corporation
PAHC offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
PAHC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Under pressure | |
| Stable |
PAHC's profitability is currently strong, and its revenue and balance sheet are stable, but its cash flow is under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
PAHC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 9.8x | $35.46 | — |
| Cheap | 14x | $35.90 | +1.2% |
| Current | 14x | $35.46 | — |
| Fair | 21x | $52.34 | +48% |
| Expensive | 37x | $93.48 | +164% |
Historical ranges are pointers, not guarantees.
PAHC has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
PAHC Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for PAHC, with profitability improving.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
PAHC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.61 | +44% |
| Q3 2026 | $2.50 | +50% |
| Q2 2026 | $2.43 | +104% |
| Q1 2026 | $2.34 | +200% |
| Q4 2025 | $2.26 | +371% |
| Q3 2025 | $1.67 | +288% |
| Q2 2025 | $1.19 | +1883% |
| Q1 2025 | $0.78 | +144% |
| Q4 2024 | $0.48 | +33% |
PAHC has the edge over LLY on earnings, with stronger typical year-over-year growth.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over PAHC on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over PAHC on profitability, with a higher operating margin.
PAHC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $386.8M | +6.3% |
| Q2 2026 | $396.7M | +4.8% |
| Q1 2026 | $383.5M | +10% |
| Q4 2025 | $373.9M | +21% |
| Q3 2025 | $363.9M | +40% |
| Q2 2025 | $378.7M | +39% |
| Q1 2025 | $347.8M | +32% |
| Q4 2024 | $309.3M | +24% |
PAHC's revenue has grown year over year for 12 quarters in a row: $387M last quarter, up 6.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 13% | -1.3 points |
| Q2 2026 | 12% | +3.2 points |
| Q1 2026 | 12% | +2 points |
| Q4 2025 | 13% | +5.2 points |
| Q3 2025 | 14% | +7.3 points |
| Q2 2025 | 8.9% | +2.2 points |
| Q1 2025 | 9.6% | +2.1 points |
| Q4 2024 | 8.3% | +2 points |
PAHC's operating margin was 13% last quarter, down 1.3 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over PAHC on cash flow, with more consistent year-over-year improvement.
PAHC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $7.3M | +$11.8M |
| Q2 2026 | $5.2M | -36% |
| Q1 2026 | $890K | -97% |
| Q4 2025 | $8.3M | +$13M |
| Q3 2025 | -$4.5M | -248% |
| Q2 2025 | $8.1M | -47% |
| Q1 2025 | $35.4M | +2011% |
| Q4 2024 | -$4.7M | -123% |
PAHC still generates free cash flow, though less than at its 2025 peak: $22M over the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over PAHC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
PAHC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -7K shares |
| 1 year | +0.2% | +80K shares |
| 3 years | +1.1% | +453K shares |
| 5 years | +1.1% | +453K shares |
| Available history | +1.1% | +453K shares |
PAHC has 41M diluted shares, about the same as a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over PAHC on leverage, with a lower net debt burden relative to earnings.
PAHC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.2x | Moderate |
| Q2 2026 | 0.2x | Very low |
| Q1 2026 | 2.5x | Moderate |
| Q4 2025 | 2.6x | Moderate |
| Q3 2025 | 2.9x | Moderate |
| Q2 2025 | 0.1x | Very low |
| Q1 2025 | 4.2x | High |
| Q4 2024 | 4.8x | High |
PAHC's net debt is about 2.2 years of its operating earnings (EBITDA), down from 2.9 years a year ago.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
PAHC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.1 | Neutral |
| Stochastic | 36.1 | Neutral |
PAHC's weekly RSI is 46 (neutral) and its Stochastic is 36 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
PAHC PE vs Healthcare Sector
| Metric | PAHC | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 26x | 45% below |
| PE % | 15 | 29 | 14 pts below |
PAHC has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over PAHC on trend strength, trading above more of its moving averages.
PAHC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $36.9 | 3.8% below |
| 20 week MA | $35.8 | 0.8% below |
| 50 week MA | $40.6 | 13% below |
| 100 week MA | $34.4 | 3% above |
| 200 week MA | $25.0 | 42% above |
PAHC has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 42% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over PAHC on returns for 2026, with the stronger performance.
PAHC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $24.8 | $19.1 | -23% |
| 2021 | $19.1 | $20.7 | +8.3% |
| 2022 | $20.7 | $13.9 | -33% |
| 2023 | $13.9 | $11.6 | -17% |
| 2024 | $11.6 | $21.1 | +82% |
| 2025 | $21.1 | $38.2 | +81% |
| 2026 YTD | $38.2 | $35.5 | -7.1% |
PAHC has finished lower in three of the last six years. It's down 7.1% so far in 2026.